Janssen Research & Development

Clinical Research Report
Protocol RIS-INT-3

R-64766 (Risperidone)

Redaction and Removal of Information in This Document

- Information (including individual data listings, where applicable) has been removed or redacted to protect the privacy of patients, study subjects, and all named persons associated with the study. Names of companies other than Janssen Research & Development or Johnson & Johnson affiliates have been redacted, unless a contractual agreement is in place with those companies to disclose their names.

- Information has been removed or redacted to protect commercially confidential information.

- Aggregate data have been included, with any direct reference to an individual patient or study subject excluded.

- To disclose as much scientifically useful data as possible, no information other than that outlined above has been removed or redacted.

Confidentiality Statement

The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or confidential.
ABSTRACT

A randomized, double-blind, placebo-controlled multicenter study compared four fixed doses of risperidone and one dose of haloperidol in schizophrenic patients. Patients were treated for eight weeks with risperidone 2, 6, 10, or 16 mg, haloperidol 20 mg, or placebo. During the first week of double-blind treatment period, fixed upward titration was required to reach the maximal dose within each treatment group. The primary measures of effectiveness were: the total score of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia and clinical improvement, defined a priori as 20% or greater reduction from baseline of the total PANSS score.

All four doses of risperidone improved psychotic symptoms. At endpoint, patients receiving risperidone 2, 6, 10, and 16 mg showed significant reduction from baseline compared to placebo in the total PANSS score and clinical improvement. Although significant improvement was shown with all doses of risperidone compared to placebo, the 6 mg group demonstrated the greatest improvement. Risperidone 6 mg was also more effective than haloperidol 20 mg in all efficacy variables. The incidence of extrapyramidal symptoms (EPS) in the risperidone 2 and 6 mg groups, as determined by patient-elicited complaints, the Extrapyramidal Symptoms Rating Scale (ESRS), or amount of EPS medication used, was similar to placebo. The occurrence of EPS increased with higher doses of risperidone but less than haloperidol. No clinically significant differences among treatment groups were detected with respect to ECG or laboratory tests, except for a dosis proportional increase in plasma prolactin levels.